Reagents News and Research

RSS

Targeting Long-read RNA Sequencing with Low-Cost Technology

Researchers at the Children’s Hospital of Philadelphia (CHOP) have created a flexible and affordable approach for targeted sequencing of full-length RNA molecules, which might hasten the development of novel diagnostics and therapies.

16 Aug 2023

New Nanopore Technology Can Identify Single-Molecule Protein Variations

A group of researchers guided by the University of Oxford has made significant progress in detecting changes in protein structures. The method, which was published in Nature Nanotechnology, uses novel nanopore technology to detect structural variations at the single-molecule level, even deep within long protein chains.

2 Aug 2023

Breakthrough in Single-Cell Genome Sequencing: New Method Reduces Bias and Expands Research Horizons

It has long been technically difficult to sequence the genome of a single bacterial cell due to the nearly impossible bias in the gene amplification stage of the process, making it difficult to produce a high-coverage genome sequence from precisely one bacterial cell.

25 Jul 2023

Next Step in Sartorius Partnership Finalized: Several Subsales and Distribution Agreements as Well as R&D Project Agreements Have Been Signed

During May and June 2023 several sub-sales and distribution agreements were signed between Sartorius and BICO companies CELLINK, Advanced BioMatrix (ABM) and Dispendix.

From BICO 5 Jul 2023

Chemical Modification Improves Non-Viral Gene Editing as Well as a New Type of DNA Repair

Gene editing is a powerful method for both research and therapy. Since the advent of the Nobel Prize-winning CRISPR/Cas9 technology, a quick and accurate tool for genome editing discovered in 2012, scientists have been working to explore its capabilities and boost its performance.

12 May 2023

Launching Revvity: A Scientific Solutions Company Powering Innovation from Discovery to Cure

Transformation aimed at revolutionizing next generation scientific breakthroughs that solve the world’s greatest health challenges

From Revvity 9 May 2023

MolGen Acquires Synchron

MolGen announced last Wednesday that it has acquired Dutch automation company Synchron Instrumenten BV, also known as Synchron Lab Automation.

From MolGen 28 Apr 2023

Revealing an Unanticipated Mechanism for Chaperone-Mediated Ribosome Repair

Researchers have discovered that if oxidative stress destroys protein factories known as ribosomes, repair crews may go in to assist in repairing the damage so that production may restart rapidly.

26 Apr 2023

Akili Labs and BGI Genomics Sign Agreement to Provide Southern Africa with Clinical-Grade Sequencing Solutions

Akili Labs (Pty) Ltd, a pioneer of cost-effective molecular diagnostics and secure genomic data storage solutions, and BGI Genomics Co. Ltd, the world's leading integrated solutions provider of precision medicine, today announced the signing of a technology transfer agreement that will provide the Southern region of Africa with clinical-grade sequencing solutions.

7 Apr 2023

Gyros Protein Technologies introduces new PurePep EasyClean services to accelerate development and manufacturing of peptide-based drugs

Gyros Protein Technologies AB today announced the launch of three service offerings to support development and manufacturing of peptide-based drugs.

From Gyros Protein Technologies AB 22 Mar 2023

Novel technology easily detects active Mycobacterium tuberculosis infection antibodies

A team of faculty from Wayne State University has discovered new technology that will quickly and easily detect active Mycobacterium tuberculosis (TB) infection antibodies.

14 Mar 2023

Novel analytical platform quantitatively characterizes mRNA vaccines

Researchers from Tokyo Metropolitan University and RIKEN CSRS have developed a new analytical platform based on liquid chromatography, mass spectrometry and software analysis that quantifies the structure of messenger RNA (mRNA) based medicines.

14 Feb 2023

Tecan collaborates with Singular Genomics to take automated NGS library preparation into the future

Tecan has partnered with Singular Genomics to use the turnkey MagicPrep™ NGS system* to create sequencing-ready libraries for the G4™ Sequencing Platform.

From Tecan 13 Feb 2023

New chemical reaction could transform drug production

Pharmaceutical synthesis is often quite complex; simplifications are needed to speed up the initial phase of drug development and lower the cost of generic production.

3 Feb 2023

The Native Antigen Company expands infectious disease portfolio to include Sudan Ebolavirus Boniface 1976 Glycoprotein

...

From The Native Antigen Company 8 Dec 2022

The analysis of pesticide residues in cannabis and hemp products

In this interview, Avinash Dalmia, the Senior Principal Application Scientist at PerkinElmer, talks to AZoLifeSciences about the analysis of 102 pesticides and 5 mycotoxin residues in hemp regulated by colorado state.

From PerkinElmer 2 Dec 2022

Gyros Protein Technologies adds Gyrolab® Biomarker Kits to expand range of ready-to-use kits and reagents

Gyros Protein Technologies AB today introduced Gyrolab® Human Cytokine Kit Reagents, the first in a range of new biomarker kits.

From Gyros Protein Technologies AB 30 Nov 2022

Lysis and hypotonic sonication buffers for ChIP assays

Offering complete disruption of cytoplasmic and nuclear membranes, Porvair Sciences Chromatrap® buffer chemistries are optimised for sonication and enzymatic shearing.

From Porvair Sciences Limited 29 Nov 2022

Applied Cells Inc. and GenScript enter strategic collaboration to deliver combined solutions for cell therapy development

November 18th, 2022. Today, Applied Cells Inc. and GenScript USA Incorporated announced their strategic collaboration to deliver combined cell isolation solutions for cell therapy drug development worldwide. Under this collaboration, GenScript will develop and supply its proprietary research and cGMP grade CytoSinct™ reagents for use in developing CAR-T and other Cell Therapy products on the Applied Cells MARS® Platform.

25 Nov 2022

The Native Antigen Company introduces new range of influenza antigens

The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the commercial launch of its latest range of influenza antigens for the southern hemisphere’s 2023 flu season.

From The Native Antigen Company 21 Nov 2022